"This publication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the objectives and potential outcomes of the research collaboration described, the potential for encapsulation to support beta cell survival and function or to reduce or avoid systemic immunosuppression, the potential advancement of any program toward commercialization, the anticipated timing of regulatory submissions by third parties, and the Company’s plans and objectives."
Framing: assertive ·
First seen: 2026-09-08 ·
Last seen: 2026-09-08 ·
Spread: 1 articles